Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection frac...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor 2024-07, Vol.30, p.e943529-e943529-10 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e943529-10 |
|---|---|
| container_issue | |
| container_start_page | e943529 |
| container_title | Medical science monitor |
| container_volume | 30 |
| creator | Yao, Zhuan'e Wang, Pengbo Fu, Qinjuan Song, Qiong Liu, Ai Li, Huan Wang, Wei Zhang, Peng |
| description | BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P |
| doi_str_mv | 10.12659/MSM.943529 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11302479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3079171092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-f38983c0c75ddd3fda5027dd30ee7f095515b3669ecba91ef5121e914bf99dd43</originalsourceid><addsrcrecordid>eNpVkUtLAzEUhYMovlfuJUtBqnlMZho3UoovUBSrbkMmubGR6UxNMkp_gv_aYFV0dQ_cj3Mu9yC0R8kRZaWQxzeTmyNZcMHkCtqkZcEHvBJk9Y_eQFsxvhDChiUR62iDD6VkkvNN9HHmnDfaLLBuLZ5oB2mBO5eV6Wufgm-On3QTdUi6xb7FlzDrrNfNIvqI73Ty0KaI332a4vE0dK03Gck0Pte-6QOc4BG-hxS6OAeT_BvgSeptTktY44lvnxvA4-wBYQetuZwEu99zGz2enz2MLwfXtxdX49H1wLCKpIHLtw-5IaYS1lrurBaEVVkRgMoRKQQVNS9LCabWkoITlFGQtKidlNYWfBudLn3nfT0Da3J40I2aBz_TYaE67dX_Teun6rl7U5RywopKZoeDb4fQvfYQk5r5aKBpdAtdHxUnlaQVJZJl9HCJmvyBGMD95lCivtpTuT21bC_T-39P-2V_6uKf2saYBA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079171092</pqid></control><display><type>article</type><title>Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Yao, Zhuan'e ; Wang, Pengbo ; Fu, Qinjuan ; Song, Qiong ; Liu, Ai ; Li, Huan ; Wang, Wei ; Zhang, Peng</creator><creatorcontrib>Yao, Zhuan'e ; Wang, Pengbo ; Fu, Qinjuan ; Song, Qiong ; Liu, Ai ; Li, Huan ; Wang, Wei ; Zhang, Peng</creatorcontrib><description>BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.943529</identifier><identifier>PMID: 38992933</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Aged ; Aminobutyrates - adverse effects ; Aminobutyrates - pharmacology ; Aminobutyrates - therapeutic use ; Angiotensin Receptor Antagonists - adverse effects ; Angiotensin Receptor Antagonists - pharmacology ; Angiotensin Receptor Antagonists - therapeutic use ; Biphenyl Compounds - therapeutic use ; Chronic Disease ; Clinical Research ; Drug Combinations ; Female ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Humans ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - physiopathology ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Quality of Life ; Renal Dialysis - methods ; Retrospective Studies ; Stroke Volume - drug effects ; Stroke Volume - physiology ; Tetrazoles - adverse effects ; Tetrazoles - pharmacology ; Tetrazoles - therapeutic use ; Treatment Outcome ; Valsartan - therapeutic use</subject><ispartof>Medical science monitor, 2024-07, Vol.30, p.e943529-e943529-10</ispartof><rights>Med Sci Monit, 2024 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302479/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302479/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38992933$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yao, Zhuan'e</creatorcontrib><creatorcontrib>Wang, Pengbo</creatorcontrib><creatorcontrib>Fu, Qinjuan</creatorcontrib><creatorcontrib>Song, Qiong</creatorcontrib><creatorcontrib>Liu, Ai</creatorcontrib><creatorcontrib>Li, Huan</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhang, Peng</creatorcontrib><title>Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.</description><subject>Aged</subject><subject>Aminobutyrates - adverse effects</subject><subject>Aminobutyrates - pharmacology</subject><subject>Aminobutyrates - therapeutic use</subject><subject>Angiotensin Receptor Antagonists - adverse effects</subject><subject>Angiotensin Receptor Antagonists - pharmacology</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Biphenyl Compounds - therapeutic use</subject><subject>Chronic Disease</subject><subject>Clinical Research</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Quality of Life</subject><subject>Renal Dialysis - methods</subject><subject>Retrospective Studies</subject><subject>Stroke Volume - drug effects</subject><subject>Stroke Volume - physiology</subject><subject>Tetrazoles - adverse effects</subject><subject>Tetrazoles - pharmacology</subject><subject>Tetrazoles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Valsartan - therapeutic use</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtLAzEUhYMovlfuJUtBqnlMZho3UoovUBSrbkMmubGR6UxNMkp_gv_aYFV0dQ_cj3Mu9yC0R8kRZaWQxzeTmyNZcMHkCtqkZcEHvBJk9Y_eQFsxvhDChiUR62iDD6VkkvNN9HHmnDfaLLBuLZ5oB2mBO5eV6Wufgm-On3QTdUi6xb7FlzDrrNfNIvqI73Ty0KaI332a4vE0dK03Gck0Pte-6QOc4BG-hxS6OAeT_BvgSeptTktY44lvnxvA4-wBYQetuZwEu99zGz2enz2MLwfXtxdX49H1wLCKpIHLtw-5IaYS1lrurBaEVVkRgMoRKQQVNS9LCabWkoITlFGQtKidlNYWfBudLn3nfT0Da3J40I2aBz_TYaE67dX_Teun6rl7U5RywopKZoeDb4fQvfYQk5r5aKBpdAtdHxUnlaQVJZJl9HCJmvyBGMD95lCivtpTuT21bC_T-39P-2V_6uKf2saYBA</recordid><startdate>20240712</startdate><enddate>20240712</enddate><creator>Yao, Zhuan'e</creator><creator>Wang, Pengbo</creator><creator>Fu, Qinjuan</creator><creator>Song, Qiong</creator><creator>Liu, Ai</creator><creator>Li, Huan</creator><creator>Wang, Wei</creator><creator>Zhang, Peng</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240712</creationdate><title>Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center</title><author>Yao, Zhuan'e ; Wang, Pengbo ; Fu, Qinjuan ; Song, Qiong ; Liu, Ai ; Li, Huan ; Wang, Wei ; Zhang, Peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-f38983c0c75ddd3fda5027dd30ee7f095515b3669ecba91ef5121e914bf99dd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aminobutyrates - adverse effects</topic><topic>Aminobutyrates - pharmacology</topic><topic>Aminobutyrates - therapeutic use</topic><topic>Angiotensin Receptor Antagonists - adverse effects</topic><topic>Angiotensin Receptor Antagonists - pharmacology</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Biphenyl Compounds - therapeutic use</topic><topic>Chronic Disease</topic><topic>Clinical Research</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Quality of Life</topic><topic>Renal Dialysis - methods</topic><topic>Retrospective Studies</topic><topic>Stroke Volume - drug effects</topic><topic>Stroke Volume - physiology</topic><topic>Tetrazoles - adverse effects</topic><topic>Tetrazoles - pharmacology</topic><topic>Tetrazoles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Valsartan - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Yao, Zhuan'e</creatorcontrib><creatorcontrib>Wang, Pengbo</creatorcontrib><creatorcontrib>Fu, Qinjuan</creatorcontrib><creatorcontrib>Song, Qiong</creatorcontrib><creatorcontrib>Liu, Ai</creatorcontrib><creatorcontrib>Li, Huan</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhang, Peng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yao, Zhuan'e</au><au>Wang, Pengbo</au><au>Fu, Qinjuan</au><au>Song, Qiong</au><au>Liu, Ai</au><au>Li, Huan</au><au>Wang, Wei</au><au>Zhang, Peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2024-07-12</date><risdate>2024</risdate><volume>30</volume><spage>e943529</spage><epage>e943529-10</epage><pages>e943529-e943529-10</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>38992933</pmid><doi>10.12659/MSM.943529</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1643-3750 |
| ispartof | Medical science monitor, 2024-07, Vol.30, p.e943529-e943529-10 |
| issn | 1643-3750 1234-1010 1643-3750 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11302479 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Aged Aminobutyrates - adverse effects Aminobutyrates - pharmacology Aminobutyrates - therapeutic use Angiotensin Receptor Antagonists - adverse effects Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Biphenyl Compounds - therapeutic use Chronic Disease Clinical Research Drug Combinations Female Heart Failure - drug therapy Heart Failure - physiopathology Humans Kidney Failure, Chronic - complications Kidney Failure, Chronic - physiopathology Kidney Failure, Chronic - therapy Male Middle Aged Quality of Life Renal Dialysis - methods Retrospective Studies Stroke Volume - drug effects Stroke Volume - physiology Tetrazoles - adverse effects Tetrazoles - pharmacology Tetrazoles - therapeutic use Treatment Outcome Valsartan - therapeutic use |
| title | Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A36%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Sacubitril/Valsartan%20in%20Hemodialysis%20Patients%20with%20Chronic%20Heart%20Failure:%20A%20Retrospective%20Study%20at%20a%20Single%20Center&rft.jtitle=Medical%20science%20monitor&rft.au=Yao,%20Zhuan'e&rft.date=2024-07-12&rft.volume=30&rft.spage=e943529&rft.epage=e943529-10&rft.pages=e943529-e943529-10&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.943529&rft_dat=%3Cproquest_pubme%3E3079171092%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3079171092&rft_id=info:pmid/38992933&rfr_iscdi=true |